Skip to main content

Table 2 Current PM adoption in four focus SEA countries based on six key themes

From: Current landscape of personalized medicine adoption and implementation in Southeast Asia

Key themes

Indicators

Indonesia

Malaysia

Singapore

Thailand

Healthcare system

General

 GDP per capita (Current USD)

3500

11,306

56,007

5970

 Healthcare financing system

Social health insurance

Tax-funded

Mixture from tax revenue, insurer and patient

Social health insurance

 Healthcare expenditure per capita (USD)

99

456

2752

360

 THE (% of GDP, 2014)

2.8

4.2

4.9

6.5

 Health coverage (%)

48

100

100

98

 OOP health expenditure (% of THE, 2014)

46.9

35.3

54.8

7.9

PM-specific

 Presence of PM-related healthcare service delivery

  1. Targeted oncology therapy

Yes

Yes

Yes

Yes

  2. PGx testing

Noa

Noa

Yesb

Yesc

  3. Newborn screening

Yes (congenital hypothyroidism)

Yes (congenital hypothyroidism, G6PD)

Yes (congenital hypothyroidism, G6PD, inherited metabolic disorders)

Yes (congenital hypothyroidism, thalassemia, phenylketonuria)

  4. Cancer risk screening

Noa

Yesd

Yesd

Noa

  5. Advance genome sequencing

No

No

Yese

Yese

 Presence of PM-related healthcare workforce

  1. Medical geneticist

Yes (NR)

Yes (9)

Yes (6 + 2 cancer geneticist)

Yes (11)

  2. Genetic counsellors

Yes (NR)

Yes (2)

Yes (≈10)

No

 Financing mechanism

  1. Capacity-building

NR

NR

NR

NR

  2. Infrastructure

NR

NR

NR

NR

  3. Research

Cyclic grants from government, university, international collaborators

Cyclic, one-off grant from government, university

Funding from A*STAR

Cyclic, one-off grant from government, university

Governance

National strategy/plan

No

No

National PM initiative (in progress)

No

Comprehensive PM legislation/guideline

No

Nof

Nof

No

Ethical, social, legal framework on PM provision

No

No

PM-specific provision standard is in progress

No

Ethical, social, legal framework for genetic data

No

Yes, but no laws related to genetic discrimination by insurance companies

PM-specific standard is in progressg

Yes, but no laws related to genetic discrimination by insurance companies

National PM research centre or large-scale research initiative

No

No

GIS; POLARIS;

SAPhIRE; PRISM

PGx projects by TCELS

Direct to consumer test legislation or code of conduct

No

No

Bioethics Advisory Committee recommendations

Existing consumer law

PM working group with multiple stakeholders

No

No

Yes

Yes

Access

HTA body

Yes

Major hospitals

Yes

National

Yes

National

Yes

National

PM-specific HTA framework

No

No

Noh

No

Multi-stakeholder decision-making group

Yes

Yes

Yes

Yes

Awareness

Patient support/advocacy groups

No

Yes

Yes, but not specific

Yes, but not specific

Efforts to increase public awareness

Yes

Yes

Yes

Yes

Patient involvement in healthcare and/or research

Low in research

Low in research

Moderate in research

High in research

Implementation

Centre of excellence/leading institute in PM service

Dr Cipto Mangunkusumo Hospital; Center for Biomedical Research in Diponegoro University

Institute of Medical Research

PRISM

Ramathibodi Hospital; Khon Kaen University Hospital; Siriraj Hospital

Education and training for PM and non-PM specialized healthcare workforce including medical school

Yes

Yes

Yes

Yes

Data

EHR

No

No

Yes

Yes

Biobank

Hospital-level biobanks

Malaysian Cohort Biobank; UKMMC-UMBI Biobank

SingHealth Tissue Repository;

National University Health System Tissue Repository

Hospital-level biobanks

Database

Indonesian National Genetic Database

Malaysian Human Variome Project

Singapore Genome Variation Project database;

Singapore Human Mutation/ Polymorphism Database; Singapore PGx Portal

Thailand Mutation and Variation database

Patient registry with genetic/genomic data

No

Thalassemia Registry

Singapore Polyposis Registry; Thalassemia Registry; National Birth Defect Registry

No

  1. Notes
  2. a Available through special request
  3. b HLA-B*15:02 screening is mandatory in Singapore. UGT1A*6 and UGT1A1*28 testing are available in National Cancer Centre
  4. c HLA-B*15:02 screening is routinely practised in major hospitals. A variety of other PGx testings are available as service in several university hospitals
  5. d BRCA screening is available in a few national/university/ specialised hospitals: University Malaya Medical Centre, Hospital Kuala Lumpur in Malaysia; National Cancer Centre Singapore, National University Hospital in Singapore
  6. e Next-generation sequencing is available in leading hospital: SingHealth-POLARIS in Singapore; Ramathibodi Hospital in Thailand
  7. f Some degree of ethical oversights are governed under the existing national medical genetics service and/or genetic testing guideline
  8. g Includes informed consent, security and confidentiality of information, and disclosure of test results to third parties outside direct healthcare providers
  9. h Genetic test is evaluated as medical device
  10. Abbreviations
  11. A*STAR Agency for Science and Technology Research, EHR electronic health record, GDP gross domestic product, GIS Genome Institute of Singapore, HTA health technology assessment, NR not reported or insufficient information, OOP out-of-pocket, PGx pharmacogenomics, PM personalized medicine, POLARIS Personalized OMIC Lattice for Advanced Research and Improving Stratification, PRISM SingHealth Duke-NUS Institute of Precision Medicine, SAPhIRE Surveillance and Pharmacogenomics Initiative for Adverse Drug Reactions, TCELS Thailand Centre of Excellence Life Sciences, THE total health expenditure, UKMMC University Kebangsaan Malaysia Medical Centre, UMBI UKM Medical Biology Institute, USD United States dollar